嵌合抗原受体T细胞治疗非霍奇金淋巴瘤的最新研究进展

非霍奇金淋巴瘤(NHL)为一组起源于T或B淋巴细胞的恶性肿瘤,约85％均来源于B淋巴细胞.NHL临床与生物学上具有很高的异质性,并且诊断、治疗及预后亦存在很大的差异.随着诊断与治疗水平的提高,大部分NHL患者均可获得长期缓解,但是部分复发/难治性NHL患者的长期生存率仍然不容乐观.近年来,过继细胞免疫治疗(ACT)发展迅猛,尤其是嵌合抗原受体T细胞(CAR-T)在治疗复发/难治性NHL方面进展迅速,其中靶向针对NHL细胞表面的CD19、CD20、CD30等抗原的CAR-T逐步成为治疗NHL的一种全新治疗手段.本文拟从CAR-T的构建、临床治疗NHL的有效性与安全性、性能优化等方面的最新研究进展进行阐述.

New research progress of chimeric antigen receptor T cell in non-Hodgkin lymphomas

Non-Hodgkin lymphomas (NHL) are a groups of malignancies with high heterogeneity,originated from T lymphocytes and B lymphocytes,and B lymphocytes counts for 85 ％ approximately.With the improvement of diagnosis,treatment,and prognosis,most NHL patients can achieve long-term remission,but curative effect of some relapsed or refractory patients are still not optimistic.Recently,there is a huge development in the treatment of relapsed or refractory NHL patients with adoptive cellular immunotherapy (ACT),especially chimeric antigen receptor T cells (CAR T).CAR-T targeting specific tumor antigens CD19,CD20,CD30,etc.,is becoming a new approach of NHL clinical treatment.This article reviews research progress of construction of CAR-T and its clinical efficacy and safety in the treatment of NHL,and function optimization.